REVB

Diving into the gritty details of this stock, let's set our sights first on Revelation Biosciences, Inc. (tickers REVB, REVBW)’s third-quarter 2023 balance sheet. We're talking about a firm with total assets amounting to $14,218,520. Current assets dominating the scene with a considerable $14,147,174, suggesting high liquidity that can come in handy for short-term obligations. Their liabilities, however, are totaled at $5,399,997. This includes $1,257,224 in accounts payable and another $4,142,773 listed under ‘other current liabilities’. Take note, investors - there's a delightful lack of long-term debt here. We might not find that in every back-alley balance sheet. Equity- oh, isn't that a criterion close to our hearts? Well, those hearts can flutter a bit knowing that equity attributable to the parent stands at $8,818,523 – surpassing liabilities by an impressive margin. Here we have an indicative measure of the company's financial stability. The lack of noncontrolling interest equity quite subtly implies that the company is sailing solo - perhaps a sign of confidence in its vision? You might call the company "asset-centric". They have their eggs mostly in non-fixed assets, given the noncurrent assets sit at only $71,346. This can mean more flexibility in liquidating assets if needed. Who doesn't love the nimbleness of a ballet dancer in their stocks? Shifting lenses towards the income statement, the company suffered a net income loss of $2,628,376 with no revenues registered. That might cause some investors to blink, but one has to consider the significant R&D expenses to the tune of $1,651,367. Displaying a classic hallmark of a potentially innovation-driven company. The company’s average shares – both basic and diluted – stood at 6,297,303 with their Earnings Per Share (EPS) at a negative of $0.42. An EPS in the red could be intimidating, yet it's commonplace in firms aggressively putting their money behind the 'next big thing'. Their net cash flow registered a clean zero, while the cash flow from operating activities revealed a deficit of $1,716,681. However, astute observers – and I dare say, that includes you – will notice an exact mirror reflection in the net cash flow from investing activities, a fascinating balancing act. Bare facts laid out, the call is yours, investors! This stock reveals a firm laden with assets, minimal liabilities, significant equity, and eager investment in R&D despite income loss. Par for the course for a company in its investment phase. Aggressive, ambitious, asset-rich, with red marks right where they could be expected – isn’t that quite the sneaky spark in the dark?